Our impact isn’t limited to the work we do in the lab. It also shows up in the way we support the communities where we live and work. Recently, we volunteered with @c2cboston, an organization working to end clothing insecurity for children across Massachusetts. Generators

The question of what will become the first AI-designed drug is no longer theoretical — the field is now testing its models against real clinical milestones. @Nature, in reporting by @ewencallaway, surveys how the field is advancing both de novo and optimization approaches to

Full Self-Driving Supervised has many times more driving experience than any human driver It's trained on >100 years of data & collectively experiences a lifetime of driving scenarios every 10 minutes

The @BosBizJournal, in a profile by @hannah_reports, spotlights @NoubarAfeyan — our co-founder and Chairman, and the founder and CEO of @FlagshipPioneer. The article looks back at 25 years of Flagship, focusing on how Noubar built an “invention machine” that repeatedly turns

All year, the question around AI in drug development has been whether it’s still mostly talk, or finally becoming real. In a new piece for the @BosBizJournal Business Journal, reporter @hannah_reports explores that question through GB-0895, our AI-engineered antibody for severe

NEW: Generate:Biomedicines is set to become the first AI-focused biotech to enter Phase 3, as the biotech will launch two late-stage asthma studies for its lead antibody The 310-employee startup has ~$240M in cash on hand, CEO Mike Nally tells me: https://t.co/ZCa0ORXMBT

Celebrate the holidays with Capcom! Iconic titles like Monster Hunter Wilds, Resident Evil 4 & Street Fighter 6 are on sale now. Don’t wait—these limited‑time deals make the perfect gift for gamers!

Progress in generative biology becomes real when a molecule performs exactly as it was designed. Today, we announced the initiation of SOLAIRIA, the first global Phase 3 studies of a long-acting anti-TSLP antibody for severe asthma. These studies will evaluate GB-0895, which

How can a small moment of appreciation reinforce how a team operates at scale? Ahead of Thanksgiving, colleagues at our Andover and Boynton Yards locations gathered for potlucks that created a brief pause in the usual pace of the day. Taking that moment together underscored

Biotech doesn’t move forward by accident. It moves forward when leaders rethink how we design, develop, and deliver medicines—and then do the work to make that real. That’s what @FlagshipPioneer recognized in our CEO, @mike_nally, with this year’s Bigger Leaps Award at their

On #WorldCOPDDay, we’re recognizing the impact of COPD and the need for more effective options for people living with this condition. According to the @GOLD_COPD, COPD is one of the leading causes of death worldwide and affects an estimated 391 million people. A single

The 2025 Limited First Edition Unity Bag has sold out within one week of launch. We are humbled and moved by the overwhelming response and love we have received. The Unity Bag was created as a quiet tribute to Fostering the Future and as a message of hope. It is the greatest

What if designing an antibody could be as systematic as writing code? On November 19 at the “AI Drug Discovery & Development Summit”, our co-founder and CTO, @ggrigoryanv, joins @elibixby of @cradlebio and Claudette Fuller of @Genmab for “AI-Driven Antibody Discovery and

“Patients can’t wait” isn’t just something we say — it’s one of our values, and it sets the standard for how we work. Yesterday, we welcomed @KathyGiusti — founder of the @theMMRF , two-time cancer survivor, and author of Fatal to Fearless — for a conversation with our Chief

As #AI redefines how medicines are discovered, it’s also testing what investors believe about value, risk, and what it takes to build a company that lasts. At @McDermottLaw’s upcoming panel, “From data to deals: AI’s impact on life sciences investing”, our CFO, Jason Silvers,

From @generate_biomed to @LilaSciences — and now Expedition Medicines — @gibsmk is helping to shape the future of company origination. Hear how she thinks about AI, learning, and the people behind pioneering innovation in her Three Questions interview.

AI Glasses to Remember Everything

Protein design isn’t just an application of #AI — it’s the test case for whether AI can meet the full complexity of biology. Yesterday at @GENbio's The State of AI in Drug Discovery 2025, moderated by @xiaofei_lin, our VP of Platform Strategy and Operations, @tharindi_h, joined

Also Oct 29: “The Rise of AI in Protein Design” — 3:00–3:30 PM EDT, part of @GENbio’s State of AI in Drug Discovery (with @SurgeBiswas, Tharindi Hapuarachchi, Oliver Vince). FREE reg: https://t.co/CHbw3Rbwfj #AI #ProteinDesign #Biotech

Flagship's latest startup launch: an AI-for-small-molecule play led by CEO Molly Gibson with $50M Expects to name a dev. candidate in the first half of 2026. Gibson was previously an exec at Flagship-founded Generate:Biomedicines and Lila: https://t.co/odZmhTuosb

How can we make the promise of #AI in cancer care real? At the @PCFnews's “32nd Annual Scientific Retreat”— a cross-disciplinary forum where leaders in academia, biotech, and medicine explore breakthroughs in #CancerResearch — Alex Therien, Ph.D., our SVP and Head of Drug Design

🚨 VICE Magazine Is Back! 2025 marks the glorious return of VICE magazine to print, marking a new golden era of weird and wonderful reportage in a totally messed-up world. Subscribe today from $2/mo.

How do you build infrastructure that turns data into a strategic asset? Stephen Kottmann, our Head of Informatics, joined @bradloncar on @BiotechTV to walk through the systems behind our design, build, test, learn loop—describing how we generate millions of sequences, move them

Our MIA 10-Year Anniversary Celebration is this Friday, October 17! 🥳 Note that this will be at 300 Binney St. (2110 - Charles) and online, and not in our usual Acadia room. We will NOT have an MIA event this Wednesday, October 15 (tomorrow). Register: https://t.co/xCRRM2WfpQ